Glaxosmithkline Stock News

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc''s (NASDAQ: VIR ) COVID-19 antibody therapy for an undisclosed sum. The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the Full story available on Benzinga.com

The new deal brings to 1 million the total number of doses of the therapy that the U.S. government has purchased, according to GlaxoSmithKline.

The US Government to purchase from GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the

GlaxoSmithKline and Vir Biotechnology have brokered a deal with the U.S. government to provide an additional 600K doses of sotrovimab for early COVID-19.

Glaxosmithkline plc - ADR (GSK) shares closed today at 1.6% below its 52 week high of $44.56, giving the company a market cap of $110B. The stock is currently down 0.6% year-to-date, up 21.0% over the past 12 months, and up 44.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 21.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -159.4% The company's stock price performance over the past 12 months lags the peer average by -38.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -34.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

(RTTNews) - 908 Devices (MASS) announced that GlaxoSmithKline (GSK) has purchased an additional REBEL cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams. REBEL is the first miniature CE-MS-based analyzer that enables biopharma researchers to accelerate

Glaxosmithkline plc - ADR (GSK) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $110B. The stock is currently up 26.8% year-to-date, up 28.6% over the past 12 months, and up 50.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 42.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -36.1% The company's stock price performance over the past 12 months lags the peer average by -26.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 21.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 27.8% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -16.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Buy Now According to the report analysis, Global Autoimmune Disorder Drug Delivery Device Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Merck KGaA, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Biogen Inc., GlaxoSmithKline Plc, Johnson Read More » The post Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research appeared first on Ken Research .